PepGen Inc. (PEPG)
NASDAQ: PEPG · Real-Time Price · USD
1.420
-0.060 (-4.05%)
Mar 31, 2025, 1:14 PM EDT - Market open

Company Description

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.

Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy.

The company was founded in 2018 and is based in Boston, Massachusetts.

PepGen Inc.
PepGen logo
Country United States
Founded 2018
IPO Date May 6, 2022
Industry Biotechnology
Sector Healthcare
Employees 81
CEO James McArthur

Contact Details

Address:
321 Harrison Avenue, 8th Floor
Boston, Massachusetts 02118
United States
Phone 781 797 0979
Website pepgen.com

Stock Details

Ticker Symbol PEPG
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $12.00
CIK Code 0001835597
CUSIP Number 713317105
ISIN Number US7133171055
SIC Code 2834

Key Executives

Name Position
Dr. James G. McArthur Ph.D. President, Chief Executive Officer, Treasurer, Secretary and Director
Noel P. Donnelly M.B.A. Chief Financial Officer
Dr. Michelle L. Mellion M.D. Chief Medical Officer
Dr. Michael Gait Ph.D. Founder and Scientific Advisory Board Member
Emiko Bryant Chief of Staff, Human Resources and Operations
David E. Borah C.F.A., M.B.A. Senior Vice President of IR and Corporate Communications
Mary Beth DeLena J.D. General Counsel and Secretary
Dr. Hayley Parker Ph.D. Senior Vice President of Global Regulatory Affairs
Dr. Afsaneh Mohebbi Ph.D. Senior Vice President of Portfolio and Program Management
Kyle Breidenstine CPA, M.B.A. Vice President of Finance and Controller

Latest SEC Filings

Date Type Title
Mar 28, 2025 8-K Current Report
Mar 4, 2025 8-K Current Report
Feb 28, 2025 SCHEDULE 13G Filing
Feb 24, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 24, 2025 8-K Current Report
Feb 24, 2025 10-K Annual Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G Filing
Feb 7, 2025 SCHEDULE 13G Filing
Feb 7, 2025 SCHEDULE 13G/A Filing